Immuno-Oncology Therapeutics

IO Therapeutics is a clinical-stage biotechnology company focused on developing innovative small molecule therapies for the treatment of cancer and autoimmune diseases. The company's lead program, IOT-022, is a dual inhibitor of Indoleamine 2,3-dioxygenase 1 (IDO1) and Tryptophan 2,3-dioxygenase (TDO), designed to overcome metabolic immunosuppression in the tumor microenvironment. By targeting both enzymes, IOT-022 aims to more effectively restore anti-tumor immune responses compared to single-target inhibitors. In addition to its oncology efforts, IO Therapeutics is advancing a pipeline of ROR gamma inverse agonists for inflammatory conditions such as psoriasis. The company is headquartered in Santa Ana, California, and leverages a lean operating model to advance its therapeutic candidates through clinical development.